A Proof of Concept Study to Evaluate the Coadministration of TT223 Given Daily and LY2428757 Given Once-Weekly for Four Weeks in Patients With Type 2 Diabetes Mellitus.
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2012
At a glance
- Drugs LY 2428757; TT 223
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 12 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Sep 2010 Results have been reported in a Transition Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History